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ABSTRACT
Objective To investigate net clinical beneﬁt (NCB) of
warfarin in individuals with atrial ﬁbrillation (AF) across
stroke risk and across primary and secondary care.
Methods We conducted a linked electronic health
record cohort study of 70 206 individuals with initial
record of diagnosis of AF in primary (n=29 568) or
secondary care (n=40 638) in England (1998–2010).
We deﬁned stroke risk according to the CHA2DS2-VASc
score, and followed individuals over a median 2.2 years
for 7005 ischaemic strokes (IS) and for 906
haemorrhagic strokes (HS). We calculated incidence rates
(IRs) and 95% CIs per 100 person-years (PYs) (IR (95%
CI)/100 PY) of IS and HS, with and without use of
warfarin, and the NCB (ie, number of IS avoided) per
100 PYs of warfarin use (NCB (95% CI)/100 PY).
Results Compared with individuals with initial record
of diagnosis in secondary care, those in primary care had
lower scores of IS risk (CHA2DS2-VASc≤2: 30.8% vs
20.6%), and lower overall incidence of IS (IR (95% CI)/
100 PY: 2.3 (2.2 to 2.4) vs 4.3 (4.2 to 4.4),
p value=0.00); however among individuals with
CHA2DS2-VASc=0, 1 or 2 there were no differences in
IS rate between those with initial record of diagnosis in
primary care or secondary care (IR (95% CI)/100 PY: 0.2
(0.1 to 0.3) vs 0.3 (0.2 to 0.5), p value=0.16), (IR
(95% CI)/100 PY: 0.6 (0.4 to 0.7) vs 0.7 (0.6 to 0.9), p
value=0.08) and (IR (95% CI)/100 PY: 1.1 (1.00 to 1.3)
vs 1.4 (1.2 to 1.6), p value=0.05), respectively. For
CHA2DS2-VASc=0, 1 and 2, IRs of IS with versus
without warfarin were (IR (95% CI)/100 PY: 0.4 (0.2 to
0.8) vs 0.2 (0.1 to 0.3), p value=0.16), (IR (95% CI)/
100 PY: 0.4 (0.3 to 0.7) vs 0.7 (0.6 to 0.8),
p value=0.03) and (IR (95% CI)/100 PY: 0.8 (0.7 to
1.0) vs 1.4 (1.3 to 1.6), p value=0.00), respectively. We
found a signiﬁcant positive NCB of warfarin from
CHA2DS2-VASc≥2 in men (NCB (95% CI)/100 PY: 0.5
(0.1 to 0.9)) and from CHA2DS2-VASc≥3 in women
(NCB (95% CI)/100 PY: 1.5 (1.1 to 1.9)).
Conclusions CHA2DS2-VASc accurately stratiﬁes IS risk
in individuals with AF across both primary and secondary
care. However, the incidence rate of ischaemic stroke at
CHA2DS2-VASc=1 are lower than previously reported,
which may change the decision to start anticoagulation
with warfarin in these individuals.
INTRODUCTION
CHA2DS2-VASc (congestive heart failure, hyper-
tension, age ≥75 years, diabetes mellitus, history
of stroke or thromboembolism, vascular disease,
age 65–74 years and female sex) is the most widely
used and validated clinical prediction score for as-
sessment of ischaemic stroke (IS) risk in individuals
with atrial ﬁbrillation (AF). The score ranges from 0
to 9, and assigns 1 or 2 points for each stroke risk
factor.1 CHA2DS2-VASc aims to identify individuals
with the lowest stroke risk (CHA2DS2-VASc=0) in
whom prevention with anticoagulants is not
advised. The advice for individuals with one stroke
risk factor (CHA2DS2-VASc=1) varies in current
clinical practice guidelines, as it remains uncertain
whether the beneﬁts of anticoagulants outweigh the
harms.2 3 4
A recent systematic review of incidence rates
(IRs) of IS in individuals with CHA2DS2-VASc=1
reported highly heterogeneous annualised rates
ranging from 0.1% to 6.6% across studies, with
wide uncertainty (0–3.23%) in the pooled estimate
of 1.6%.5 Among the 10 included studies, there
were 0 studies that involved individuals across both
primary and secondary care. Primary care accounts
for over 40% of initial AF diagnoses.6 Therefore
without the inclusion of these individuals, it is
unclear whether previously reported stroke rates
are representative of the full patient pathway.
Furthermore, in many countries (including the
UK, Denmark and Sweden) clinical information
coded and recorded electronically in secondary
care is not integrated with that of primary care.7
Thus, without the inclusion of risk factors diag-
nosed in primary care, previous studies based
on secondary care data may have inaccurately
calculated individuals’ CHA2DS2-VASc scores
(ﬁgure 1).8 Lastly, without conducting net clinical
beneﬁt (NCB) analyses, which weigh up beneﬁts
and harms of anticoagulants, the review was
limited in the extent to which it could inform
recommendations for clinical practice guidelines.
We therefore implemented the CHA2DS2-VASc
score in a large, nationally representative linked
electronic health record (EHR) study of 70 206
individuals with initial record of diagnosis of non–
valvular AF in primary or secondary care in
England in 1998–2010. We selected an observation
period prior to the introduction of direct oral
anticoagulants (DOACs), in order to more accur-
ately study outcomes with warfarin. Our objectives
were (1) to investigate incidence of IS in individuals
with AF across stroke risk and across primary and
secondary care, and (2) to consider beneﬁts and
harms of warfarin in NCB analyses.
Allan V, et al. Heart 2016;0:1–9. doi:10.1136/heartjnl-2016-309910 1
Arrhythmias and sudden death
 Heart Online First, published on August 31, 2016 as 10.1136/heartjnl-2016-309910
Copyright Article author (or their employer) 2016. Produced by BMJ Publishing Group Ltd (& BCS) under licence. 
group.bmj.com on September 24, 2016 - Published by http://heart.bmj.com/Downloaded from 
METHODS
Data sources
We used available data from the population-based CALIBER
(ClinicAl research using LInked Bespoke studies and EHRs)
study.7 CALIBER connects four national sources of EHRs in
England, including a subset of primary care data from the
Clinical Practice Research Datalink GP OnLine Database (CPRD
GOLD),9 secondary care data from Hospital Episode Statistics
(HES),10 data on admissions to hospital with an acute coronary
syndrome from the Myocardial Ischaemic National Audit
Project11 and cause-speciﬁc mortality data from the Ofﬁce of
National Statistics (ONS).12 The denominator population com-
prises individuals captured in CPRD GOLD, who are represen-
tative of the UK population in terms of gender, age, ethnicity13
and overall mortality.14 For this analysis we used CPRD GOLD,
HES and ONS. CPRD GOLD is coded using Read clinical
terms,15 and HES and ONS using the International
Classiﬁcation of Diseases V.10 (ICD–10).16 A key objective of
CALIBER is to facilitate transparent and reproducible research
of these data through the publication of disease phenotypes and
tools to support statistical analysis, and these can be found
freely available at caliberresearch.org. CALIBER research has
been shown to replicate known and discover new associations
with risk factors for the onset of disease.17–20
Selection of individuals with non-valvular AF
We used the previously reported CALIBER phenotype algorithm
for AF to identify all individuals with a diagnosis in primary or
secondary care between 1998 and 2010.6 The algorithm
includes primary and secondary care (main and subsidiary)
recorded diagnoses, and inferred diagnoses based on warfarin
prescriptions without prior thromboembolic disease. In order to
deﬁne non-valvular AF we then excluded individuals with a
record of mitral valve disease, rheumatic mitral regurgitation,
and prosthetic mitral, aortic or unspeciﬁed valve replacements,21
based on 45 Read codes, 9 ICD–10 codes and 11 operation and
procedure codes (see online supplementary table S1 for the
code list).
CHA2DS2-VASc
We generated baseline CHA2DS2-VASc scores for each individual
by assigning 1 or 2 points for each stroke risk factor. Risk
factors were deﬁned according to existing CALIBER phenotypes
(available at caliberresearch.org), which use all available clinical
information across the linked primary and secondary care
records. In brief, age and sex were obtained from general prac-
tice registration information; congestive heart failure, diabetes
mellitus (types I, II and unclassiﬁed), history of stroke or
thromboembolism (stroke, transient ischaemic attack or systemic
embolism), and vascular disease (myocardial infarction (MI) or
peripheral artery disease (PAD)) from clinical diagnosis codes;
and hypertension from diagnosis codes, two or more values of
systolic or diastolic blood pressure measurements above UK
diagnostic thresholds of 140/90 mm Hg,22 or through repeat
prescriptions for blood pressure lowering medications.
Warfarin
We considered warfarin use throughout the entire study period
and extracted information on prescriptions and international
normalised ratio (INR) tests from primary care records.
Prescriptions data include drug type and date of administration
but do not have information on pharmacy collections.
Individuals were considered to be using warfarin continuously
during follow-up if a prescription or INR test was administered
every 30 days. This allowed each individual’s follow-up time to
be divided into periods with and without use of warfarin.23
Follow-up and end points
Individuals entered the study at their earliest coded diagnosis of
AF during January 1998 and March 2010, provided they were
aged 18 years and over and with a minimum of 1 year of con-
tinuous registration at a general practice with acceptable data
recording standards. We followed individuals for clinical diagno-
ses of IS and unclassiﬁed strokes, and for haemorrhagic strokes
(HSs) (intracerebral and subarachnoid haemorrhage) as recorded
in primary or secondary care and mortality registry records. ISs
and unclassiﬁed strokes were combined, as it has previously
Figure 1 Example of one patient’s actual pathway and how information is captured in primary care and secondary care records. This illustrates
how lack of integration of primary and secondary care information may lead to underestimation of CHA2DS2-VASc scores. Patient interactions
occurring in primary and secondary care are colour-coded green and blue, respectively. +1 indicates scoring of one CHA2DS2-VASc risk factor point.
As shown, this patient has CHA2DS2-VASc=1 based on secondary care records only, CHA2DS2-VASc=2 based on primary care records only, but is
truly CHA2DS2-VASc=3 based on integrated primary and secondary care records. INR, International Normalised Ratio.
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been shown that 87% of all strokes are ischaemic.24 A clearance
period of 2 weeks was imposed from date of recorded AF diag-
nosis, such that any stroke occurring during this time was attrib-
uted to baseline risk and not counted as an end point. The
rationale is that AF is commonly ﬁrst detected when an individ-
ual presents with a complication, such as stroke.25 Clearance
periods are also imperative when analysing linked EHRs to
avoid double counting, as the same event can be recorded more
than once, and in multiple data sources.26 Total follow-up time
for each individual was calculated as the number of days from
the end of the clearance period to the point of censoring.
Individuals were censored in the event of an IS or HS end
point, death (from a cause other than a stroke end point), trans-
fer out of general practice, or last date of data collection.
Data analysis
We compared baseline CHA2DS2-VASc risk factors in individuals
with initial record of diagnosis in primary and secondary care
using the Student’s t-test or χ2 test, and these are presented as
proportions, means (SD) and medians (range, IQR), as appropri-
ate. We assessed the completeness of recording CHA2DS2-VASc
risk factors in each data source using absolute proportions, that
is, number (%) of total cases captured in primary care records,
and in secondary care records, compared with both data sources
linked. We calculated IRs and 95% CIs per 100 person-years
(PYs) (IR (95% CI)/100 PY) for IS and HS by dividing the
number of end points by the accrued number of PYs. We
assessed whether IRs were robust by comparing with estimates
adjusted for propensity score quintiles. This accounts for
whether individuals were more likely or less likely to receive
treatment with warfarin. We conducted NCB analyses compar-
ing number of ISs avoided, against number of HSs experienced
per 100 PYs of warfarin use (NCB (95% CI)/100 PY). We used
the formula: (IS ratewithout warfarin−IS ratewith warfarin)−1.5 (HS
ratewith warfarin−HS ratewithout warfarin), whereby a positive esti-
mate indicates a treatment beneﬁt, and a negative estimate indi-
cates treatment harm.27 We regarded the NCB as signiﬁcant if
the 95% CI did not span both the positive and negative scales.
All analyses were conducted in Stata/SE V.13 and ﬁgures were
generated in R (V.3.2.0).
RESULTS
Population characteristics
Population overall
The overall study population comprised 70 206 individuals with
non-valvular AF with median age of 77.9 years (range: 18.0–
108.7, IQR: 15.1), and median follow-up of 2.20 years (range:
0.03–12.2, IQR: 4.2). Of the individuals 34 286 (48.8%) were
women, and 2486 (3.5%) had CHA2DS2-VASc=0, 5637 (8.0%)
had CHA2DS2-VASc=1 and 9339 (13.3%) had CHA2DS2-
VASc=2. The mean (SD) CHA2DS2-VASc score of the overall
population was 3.7 (1.8).
Individuals with initial record of diagnosis in primary versus
secondary care
Of the individuals 29 568 (42.1%) had initial record of diagno-
sis of AF in primary care, and 40 638 (57.9%) had initial record
of diagnosis in secondary care. Individuals with initial record of
diagnosis in secondary care were older (median (IQR) age: 79.1
(15.0) years vs 76.5 (14.8) years), more likely to be female
(50.1% vs 47.1%) and were less likely to have CHA2DS2-
VASc=0 (2.9% vs 4.4%), CHA2DS2-VASc=1 (6.6% vs 10.1%)
or CHA2DS2-VASc=2 (11.1% vs 6.6%) than those with initial
record of diagnosis in primary care. The mean (SD) CHA2DS2-
VASc score among individuals with initial record of diagnosis of
AF in primary care compared with secondary care was 3.3 (1.7)
vs 4.0 (1.8). As table 1 shows, individuals with initial record of
diagnosis in secondary care had a higher proportion of all
CHA2DS2-VASc risk factors.
Individuals with versus without use of warfarin
Of the individuals 30 067 (42.8%) underwent at least one
period of warfarin use during follow-up; 50.1% of these had
initial record of diagnosis in primary care (n=15 077) and
49.9% had initial record of diagnosis in secondary care
(n=14 990). Individuals without use of warfarin were older
(median (IQR) age: 80.7 (15.2) years vs 74.9 (13.4) years) and
had a higher proportion of heart failure, but there was no differ-
ence in diagnosed hypertension, vascular disease (MI or PAD),
diabetes and previous strokes, when compared with those with
at least one period of warfarin use (see online supplementary
table S2).
Men versus women
Women were older (median (IQR) age: 80.8 (13.3) years vs
74.9 (15.9) years) and had a higher proportion of heart failure,
hypertension and previous strokes, while vascular disease (MI
and PAD) and diabetes were more common in men (see online
supplementary table S3).
Completeness of risk factors and reclassiﬁcation
of CHA2DS2-VASc scores
The completeness of recording CHA2DS2-VASc risk factors in
primary and secondary care records ranged from 40.4% to
73.7% complete in secondary care records, and from 69.1% to
99.0% in primary care records (see online supplementary table
S4 and ﬁgure S1). Among individuals with initial record of diag-
nosis in secondary care, 975 (45.2%) were reclassiﬁed from
CHA2DS2-VASc=0 to CHA2DS2-VASc≥1 and 2172 (53.7%)
from CHA2DS2-VASc=1 to CHA2DS2-VASc≥2 when scores
were calculated using linked primary–secondary care records.
Only 15 (1.1%) individuals with initial record of diagnosis in
primary care were reclassiﬁed from CHA2DS2-VASc=0 to
CHA2DS2-VASc≥1 and 81 (2.7%) from CHA2DS2-VASc=1 to
CHA2DS2-VASc≥2. For CHA2DS2-VASc scores calculated based
on primary and secondary care records compared with both
data sources linked, see online supplementary table S5.
Stroke incidence
IS incidence in individuals with initial record of diagnosis
in primary or secondary care
Seven thousand and ﬁve ISs occurred over 216 446 PYs, with IR
(95% CI)/100 PYof 3.2 (3.2 to 3.3). Compared with individuals
with initial record of diagnosis in secondary care, those in
primary care had lower overall IS incidence (IR (95% CI)/
100 PY: 2.3 (2.2 to 2.4) vs 4.3 (4.2 to 4.4), p value=0.00),
however as ﬁgure 2 shows there were no differences in incidence
at CHA2DS2-VASc=0 (IR (95% CI)/100 PY: 0.2 (0.1 to 0.3) vs
0.3 (0.2 to 0.5), p value=0.16), CHA2DS2-VASc=1 (IR (95%
CI)/100 PY: 0.6 (0.4 to 0.7) vs 0.7 (0.6 to 0.9), p value=0.08) or
CHA2DS2-VASc=2 (IR (95% CI)/100 PY: 1.1 (1.00 to 1.3) vs 1.4
(1.2 to 1.6), p value=0.05). IRs in individuals with initial record
of diagnosis in primary or in secondary care across all
CHA2DS2-VASc scores are provided in table 2.
IS incidence by warfarin use
One thousand and ﬁfteen (14.5%) ISs occurred over 59 006 PYs
of warfarin use and 5990 (85.5%) over 157 439 PYs of no
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warfarin use. IRs were lower with warfarin use (IR (95% CI)/
100 PY: 1.7 (1.6 to 1.8) vs 3.8 (3.7 to 3.9), p value=0.00), with
an IR ratio (95% CI) of 0.5 (0.4 to 0.5). For CHA2DS2-VASc=0,
CHA2DS2-VASc=1 and CHA2DS2-VASc=2, IRs with versus
without use of warfarin were (IR (95% CI)/100 PY: 0.4 (0.2 to
0.8) vs 0.2 (0.1 to 0.3), p value=0.16), (IR (95% CI)/100 PY: 0.4
(0.3 to 0.7) vs 0.7 (0.6 to 0.8), p value=0.03) and (IR (95% CI)/
100 PY: 0.8 (0.7 to 1.0) vs 1.4 (1.3 to 1.6), p value=0.00). As
ﬁgures 3 and 4 show IRs were lower with use of warfarin from
CHA2DS2-VASc≥2 in men (IR (95% CI)/100 PY: 0.9 (0.7 to 1.1)
vs 1.7 (1.5 to 1.9), p value=0.00), and from CHA2DS2-VASc≥3
in women (IR (95% CI)/100 PY: 0.7 (0.5 to 1.0) vs 2.3 (2.0 to
2.5), p value=0.00). IRs by sex and use of warfarin across all
CHA2DS2-VASc scores are provided in table 3. IRs adjusted for
propensity score quintiles were consistent with the unadjusted
estimates (see online supplementary table S6).
NCB of warfarin
Nine hundred and six HSs occurred over 224 777 PYs. The
overall NCB of warfarin was 1.9 (1.8 to 2.1) ISs avoided per
100 PYs. For CHA2DS2-VASc=0, CHA2DS2-VASc=1 and
CHA2DS2-VASc=2, NCB was (NCB (95% CI)/100 PY: −0.3
(−0.8 to 0.1)), (NCB (95% CI)/100 PY: 0.1 (−0.2 to 0.4)) and
(NCB (95% CI)/100 PY: 0.2 (−0.1 to 0.6)), respectively. A sig-
niﬁcant positive NCB was observed from CHA2DS2-VASc≥2 in
men (NCB (95% CI)/100 PY: 0.5 (0.1 to 0.9)) and from
Table 1 Comparison of baseline CHA2DS2-VASc risk factors in individuals with initial record of diagnosis in primary or secondary care
Initial record of diagnosis
Primary care Secondary care Population overall
Number of individuals
29 568 40 638 70 206
N Per cent N Per cent N Per cent
Congestive heart failure 4768 16.1 12 664 31.2 17 432 24.8
Hypertension 23 946 81.0 33 817 83.2 57 763 82.3
Diagnosis 16 616 56.2 25 273 62.2 41 889 59.7
Blood pressure medication 20 979 71.0 30 164 74.2 51 143 72.9
Blood pressure measures 17 281 58.4 22 329 55.0 39 610 56.4
Age ≥ 75 years2 16 318 55.2 25 872 63.7 42 190 60.1
Diabetes 3316 11.2 6673 16.4 9989 14.2
Stroke/transient ischaemic attack/
systemic embolism2
3887 13.2 8938 22.0 12 825 18.3
Vascular disease 4049 13.7 9783 24.1 13 832 19.7
Myocardial infarction 2635 8.9 6950 17.1 9585 13.7
Peripheral vascular disease 1776 6.0 3927 9.7 5703 8.1
Age 65–74 years 7744 26.2 8552 21.0 16 296 23.2
Sex category (female) 13 930 47.1 20 356 50.1 34 286 48.8
CHA2DS2-VASc scores
0 1305 4.4 1181 2.9 2486 3.5
1 2972 10.1 2665 6.6 5637 8.0
2 4820 16.3 4519 11.1 9339 13.3
3 6663 22.5 7107 17.5 13 770 19.6
4 7332 24.8 9578 23.6 16 910 24.1
5 3712 12.6 7514 18.5 11 226 16.0
6 1866 6.3 4906 12.1 6772 9.7
7 724 2.5 2341 5.8 3065 4.4
8 156 0.5 707 1.7 863 1.2
9 18 0.1 120 0.3 138 0.2
Figure 2 Incidence rates (95% CIs) per 100 person-years of ischaemic
stroke by CHA2DS2-VASC scores in individuals with initial record of
diagnosis in primary or secondary care.
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CHA2DS2-VASc≥3 in women (NCB (95% CI)/100 PY: 1.5 (1.1
to 1.9)). NCB estimates across all CHA2DS2-VASc scores are
provided in table 4.
DISCUSSION
We conducted the ﬁrst large-scale nationally representative study
of the potential beneﬁts and harms of warfarin in individuals
with AF across stroke risk and across primary and secondary
care, and had two major ﬁndings. First, we conﬁrmed that
CHA2DS2-VASc accurately stratiﬁes stroke risk in individuals
with initial record of diagnosis in primary and secondary care,
however clinical information recorded in both primary and sec-
ondary care must be considered in order to correctly assign
CHA2DS2-VASc scores. Second, in individuals who were truly
CHA2DS2-VASc=1, the absolute risk of IS (0.4 (0.3 to 0.7) with
warfarin, and 0.7 (0.6 to 0.8) without warfarin) was relatively
low and similar to the original derivation cohort of the
CHA2DS2-VASc score,
1 and the NCB of warfarin was positive
but non-signiﬁcant (0.1 (−0.2 to 0.4)). We therefore found
insufﬁcient evidence to support anticoagulation with warfarin in
individuals with CHA2DS2-VASc=1.
Findings in context
Our IS IR of 0.7 (0.6 to 0.8) for CHA2DS2-VASc=1 without
warfarin is low compared with previous reports (see online sup-
plementary table S7) although consistent with the levels of
uncertainty in a recent systematic review which reported an
annual rate of 1.6% but with wide CIs (0% to 3.23%). Three
lines of evidence from sensitivity analyses in men with
CHA2DS2-VASc=1 (see online supplementary table S8) suggest
that our estimates of stroke incidence are likely to be robust and
offer reasons why they may differ from previous reports. First,
Table 2 Incidence rates (95% CIs) per 100 person-years of ischaemic stroke by CHA2DS2-VASC scores in individuals with initial record of
diagnosis in primary or secondary care
Initial record of diagnosis
Primary care Secondary care
p Value
Population overall
Events Rate Events Rate Events Rate
CHA2DS2-VASc scores
0 12 0.2 (0.1 to 0.3) 16 0.3 (0.2 to 0.5) 0.16 28 0.2 (0.2 to 0.4)
1 77 0.6 (0.4 to 0.7) 76 0.7 (0.6 to 0.9) 0.08 153 0.6 (0.5 to 0.7)
2 244 1.1 (1.0 to 1.3) 209 1.4 (1.2 to 1.6) 0.05 453 1.2 (1.1 to 1.3)
3 528 2.0 (1.8 to 2.2) 485 2.4 (2.2 to 2.6) 0.01 1013 2.2 (2.0 to 2.3)
4 766 2.9 (2.7 to 3.2) 907 3.9 (3.7 to 4.2) 0.00 1673 3.4 (3.2 to 3.6)
5 450 3.9 (3.5 to 4.2) 966 6.5 (6.1 to 6.9) 0.00 1416 5.3 (5.1 to 5.6)
6 332 6.4 (5.7 to 7.1) 1028 12.0 (11.3 to 12.8) 0.00 1360 9.9 (9.4 to 10.4)
7 146 7.7 (6.6 to 9.1) 546 14.8 (13.6 to 16.1) 0.00 692 12.4 (11.5 to 13.3)
8 34 9.3 (6.6 to 12.9) 151 15.8 (13.5 to 18.5) 0.00 185 13.9 (12.1 to 16.1)
9 5 13.4 (5.6 to 32.3) 27 22.1 (15.2 to 32.3) 0.31 32 20.0 (14.2 to 28.4)
0–9 2594 2.3 (2.2 to 2.4) 4411 4.3 (4.2 to 4.42) 0.00 7005 3.2 (3.2 to 3.3)
Bold text is used to differentiate the rates among individual scores 0,1, 2, …, 9, from all scores 0 to 9 combined.
Figure 3 Incidence rates (95% CIs) per 100 person-years of ischaemic
stroke in men by CHA2DS2-VASC scores, and use of warfarin. Individuals
could contribute follow-up time to periods with and without warfarin.
Figure 4 Incidence rates (95% CIs) per 100 person-years of ischaemic
stroke in women by CHA2DS2-VASC scores, and use of warfarin.
Individuals could contribute follow-up time to periods with and without
warfarin.
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as found in our main analysis, secondary care records underesti-
mate stroke risk in half of individuals, and therefore previous
studies which have predominantly focused on secondary care
populations are likely to be biased by misclassiﬁcation of
CHA2DS2-VASc scores. In a sensitivity analysis of men with
CHA2DS2-VASc=1 according to secondary care records (which
included 53% who were truly CHA2DS2-VASc≥2), we found an
IR of 1.4 (1.2 to 1.5), which is twice as high as the rate found
for men who were truly CHA2DS2-VASc=1 (0.7 (0.6 to 0.8))
and similar to the meta-analysed rate found in the recent sys-
tematic review (1.6 (0 to 3.23)). Importantly, we conﬁrm that if
CHA2DS2-VASc risk is underestimated then stroke rates at the
lower end of the CHA2DS2-VASc scale are overestimated, which
has implications on treatment decisions. Second, Friberg, et al25
reported that variation in the literature also exists because of dif-
ferences in the way stroke is deﬁned, and that a 44% higher IR
is observed when including wider thromboembolic end points.
We also conﬁrmed this in a sensitivity analysis, and found that
for men with CHA2DS2-VASc=1, the IR doubled from 0.7 (0.6
to 0.8) to 1.4 (1.2 to 1.5) when systemic embolism, pulmonary
embolism and transient ischaemic attacks were included as a
composite end point. Third, differences in previously reported
stroke rates at CHA2DS2-VASc=1 may exist because not all
1-point scoring risk factors (heart failure, hypertension, diabetes
mellitus, vascular disease, age 65–74 years, female sex) confer
the same stroke risk.28 In sensitivity analyses, we found that age
65–74 years conferred the highest stroke risk with IR of 1.2
(0.9 to 1.5). Thus, population-based IRs of CHA2DS2-VASc=1
will depend upon the distribution of 1-point scoring risk factors
within the population.
Unlike the recent systematic review, our ﬁndings with regard
to CHA2DS2-VASc=1 are supported by NCB analyses. To our
knowledge, this is the ﬁrst NCB analysis of warfarin to date that
includes both individuals with initial record of diagnosis in
primary and secondary care. We found a positive but non-
signiﬁcant treatment beneﬁt of warfarin in individuals with
CHA2DS2-VASc=1 (0.1 (−0.2 to 0.4)), and therefore insufﬁ-
cient evidence to support anticoagulation with warfarin in these
individuals. Existing NCB analyses of warfarin have predomin-
antly focused on individuals with initial record of diagnosis in
secondary care, but have also shown an unclear beneﬁt of treat-
ment at CHA2DS2-VASc=1, including in both the nationwide
Table 3 Incidence rates (95% CIs) per 100 person-years of ischaemic stroke by CHA2DS2-VASC scores, sex and use of warfarin
With warfarin Without warfarin Population overall
Events Rate Events Rate p Value Events Rate
CHA2DS2-VASc scores
Overall population
0 7 0.4 (0.2 to 0.8) 21 0.2 (0.1 to 0.3) 0.23 28 0.2 (0.2 to 0.4)
1 27 0.4 (0.3 to 0.7) 126 0.7 (0.6 to 0.8) 0.03 153 0.6 (0.5 to 0.7)
2 87 0.8 (0.7 to 1.0) 366 1.4 (1.3 to 1.6) 0.00 453 1.2 (1.1 to 1.3)
3 144 1.0 (0.9 to 1.2) 869 2.6 (2.5 to 2.8) 0.00 1013 2.2 (2.0 to 2.3)
4 226 1.7 (1.5 to 2.0) 1447 4.0 (3.8 to 4.2) 0.00 1673 3.4 (3.2 to 3.6)
5 233 3.2 (2.8 to 3.6) 1183 6.2 (5.8 to 6.5) 0.00 1416 5.3 (5.1 to 5.6)
6 159 4.2 (3.6 to 4.8) 1201 12.1 (11.4 to 12.8) 0.00 1360 9.9 (9.4 to 10.4)
7 111 7.1 (5.9 to 8.6) 581 14.5 (13.4 to 15.7) 0.00 692 12.4 (11.5 to 13.4)
8 18 4.8 (3.0 to 7.6) 167 17.6 (15.1 to 20.5) 0.00 185 14.0 (12.1 to 16.2)
9 3 7.5 (2.4 to 23.3) 29 24.3 (16.9 to 35.0) 0.03 32 20.1 (14.2 to 28.4)
0–9 1015 1.7 (1.6 to 1.8) 5990 3.8 (3.7 to 3.9) 0. 00 7005 3.2 (3.2 to 3.3)
Men
0 7 0.4 (0.2 to 0.8) 21 0.2 (0.1 to 0.3) 0.23 28 0.2 (0.2 to 0.4)
1 25 0.5 (0.3 to 0.7) 112 0.8 (0.6 to 0.9) 0.01 137 0.7 (0.6 to 0.8)
2 75 0.9 (0.7 to 1.1) 306 1.7 (1.5 to 1.9) 0.00 381 1.5 (1.3 to 1.6)
3 106 1.3 (1.1 to 1.5) 550 2.9 (2.7 to 3.2) 0.00 656 2.4 (2.2 to 2.6)
4 119 2.2 (1.8 to 2.6) 489 4.3 (3.9 to 4.7) 0.00 608 3.6 (3.3 to 3.9)
5 122 4.1 (3.4 to 4.9) 491 7.8 (7.1 to 8.5) 0.00 613 6.6 (6.1 to 7.1)
6 51 4.1 (3.1 to 5.4) 312 11.5 (10.3 to 12.9) 0.00 363 9.2 (8.3 to 10.1)
7 27 6.1 (4.3 to 9.2) 129 14.5 (12.2 to 17.3) 0.00 156 11.9 (10.1 to 13.9)
8 1 1.9 (0.3 to 13.3) 20 14.5 (9.4 to 22.5) 0.01 21 11.0 (7.2 to 16.8)
0–8 533 1.6 (1.4 to 1.7) 2430 2.9 (2.8 to 3.1) 0.00 2963 2.5 (2.4 to 2.6)
Women
1 2 0.4 (0.1 to 1.5) 14 0.4 (0.2 to 0.7) 0.97 16 0.4 (0.3 to 0.7)
2 12 0.5 (0.3 to 0.9) 60 0.7 (0.6 to 0.9) 0.24 72 0.7 (0.5 to 0.8)
3 38 0.7 (0.5 to 1.0) 319 2.3 (2.0 to 2.5) 0.00 357 1.8 (1.6 to 2.0)
4 107 1.4 (1.1 to 1.7) 958 3.9 (3.7 to 4.1) 0.00 1065 3.3 (3.1 to 3.5)
5 111 2.5 (2.1 to 3.0) 692 5.4 (5.0 to 5.8) 0.00 803 4.7 (4.4 to 5.0)
6 108 4.2 (3.5 to 5.0) 889 12.3 (11.5 to 13.1) 0.00 997 10.2 (9.5 to 10.8)
7 84 7.4 (6.0 to 9.2) 452 14.5 (13.2 to 15.9) 0.00 536 12.6 (11.6 to 13.7)
8 17 5.3 (3.3 to 8.5) 147 18.1 (15.4 to 21.3) 0.00 164 14.5 (12.4 to 16.9)
9 3 7.5 (2.4 to 23.3) 29 24.3 (16.9 to 35.0) 0.03 32 20.1 (14.2 to 28.4)
1–9 482 2.0 (1.8 to 2.1) 3560 4.8 (4.6 to 4.9) 0.00 4042 4.1 (3.9 to 4.2)
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Danish (−0.02 (−0.15 to 0.11)),29 and Swedish (0.00 (not
reported))30 cohorts.
Direct oral anticoagulants
A question that remains is whether the newer DOACs (dabiga-
tran, rivaroxaban, apixaban and edoxaban) have a role in the
treatment of lower-risk individuals. In DOAC trials (eg, rando-
mized evaluation of long-term anticoagulant therapy (RE-LY),31
rivaroxaban once daily oral direct factor xa inhibition compared
with vitamin k antagonism for prevention of stroke and embol-
ism trial in atrial ﬁbrillation (ROCKET-AF),32 apixaban for
reduction in stroke and other thromboembolic events in atrial
ﬁbrillation (ARISTOTLE)33 and effective anticoagulation with
factor xa next generation in atrial ﬁbrillation–thrombolysis in
myocardial Infarction 48 (ENGAGE AF-TIMI 48)34) all four
agents were shown to be as effective in preventing ISs as war-
farin, and associated with fewer HSs (see online supplementary
table S9). We applied the trial reported relative risks of IS and
HS to our data to consider the NCB of DOACs compared with
no treatment. We found a signiﬁcant positive NCB at
CHA2DS2-VASc=1 across all agents (see online supplementary
table S10), and therefore some, although extrapolated evidence
that DOACs may be a more suitable treatment option for those
at lower stroke risk. We caution against interpreting this ﬁnding
too strongly, however, as the extrapolated model takes on mul-
tiple assumptions. First, it assumes that the relative risk reduc-
tion is constant over the entire period of follow-up, and across
all levels of the CHA2DS2-VASc score. Second, it assumes that
the trial population is representative of the general AF popula-
tion. And third, it assumes that the beneﬁt and harm end point
deﬁnitions are equivalent. All four DOAC trials were approxi-
mately 2 years in duration, which is comparable to the 2.2
median years of follow-up in this analysis. However based on
trial eligibility criteria, patients at CHA2DS2-VASc=1 were
largely excluded from DOAC trials, and as previously demon-
strated these trials represented only a half to two-thirds of the
AF population in the UK.35 Lastly, beneﬁt and harm end point
deﬁnitions did vary across trials (see online supplementary table
S9).
Clinical implications
We conﬁrmed that CHA2DS2-VASc is valid for estimating stroke
risk in individuals with initial record of diagnosis in primary
and secondary care, and therefore advocate use of the score
across the full patient pathway. While we showed that lack of
integration of primary and secondary care information may lead
to inaccurate CHA2DS2-VASc scores, we do not regard this as
an issue at point of care as clinicians are able to verify stroke
risk factors with patients directly. However with the advent of
clinical decision support systems,36 greater integration of
primary and secondary care, and better recording of risk factors
is urgently required in order to avoid undue patient harm
through underestimation of stroke risk. Finally, we found insufﬁ-
cient evidence to support stroke prevention with warfarin at
CHA2DS2-VASc=1, and this may have relevance for future
treatment guidelines.37
Research implications
Our ﬁndings highlight the value of linked EHRs in investigating
individuals across the full pathway of primary and secondary
care, and crucially in identifying individuals with
CHA2DS2-VASc=1 in whom treatment guidelines have so far
been unclear. Primary care records were instrumental in identi-
fying individuals with CHA2DS2-VASc=1 and we therefore
propose wider utilisation of existing and discovery of new
primary care data sources for studying these individuals in
future research, and in particular in ‘real-world’ comparative
effectiveness studies of DOACs. By comparison, several
large-scale secondary care data sources have already been used
in AF research,25 28 38 however these are currently limited in
terms of depth of clinical information, such as lack of prescrip-
tions or biomarker data. We therefore propose wider linkage of
routinely collected records to other clinical data sources such as
disease-speciﬁc registries where deeper phenotype information
is contained.
Strengths and limitations
Our study’s principal strength was the inclusion of individuals,
risk factors and end points captured across the full pathway of
primary and secondary care, which is unlike previous studies
that have predominantly focused on secondary care populations.
We were limited by the depth and completeness of clinical infor-
mation currently recorded in primary and secondary care
records, however, we minimised the impact of this by analysing
Table 4 Net clinical benefit (95% CIs) per 100 person-years with
warfarin, by CHA2DS2-VASC scores and sex
Total stroke events
Net clinical benefitIschaemic stroke Haemorrhagic stroke
CHA2DS2-VASc scores
Overall population
0 28 8 −0.3 (−0.8 to 0.1)
1 153 54 0.1 (−0.2 to 0.4)
2 453 95 0.2 (−0.1 to 0.6)
3 1013 165 1.5 (1.2 to 1.8)
4 1673 237 2.2 (1.8 to 2.6)
5 1416 180 3.2 (2.6 to 3.8)
6 1360 104 7.7 (6.7 to 8.8)
7 692 45 7.2 (5.2 to 9.1)
8 185 18 12.8 (8.9 to 16.9)
9 32 0 16.8 (1.8 to 31.5)
0–9 7005 906 1.9 (1.8 to 2.1)
Men
0 28 8 −0.3 (−0.8 to 0.1)
1 137 48 0.1 (−0.2 to 0.4)
2 381 79 0.5 (0.1 to 0.9)
3 656 103 1.5 (1.1 to 1.9)
4 608 93 2.0 (1.3 to 2.7)
5 613 88 3.9 (2.6 to 4.9)
6 363 26 7.1 (5.2 to 9.1)
7 156 15 8.6 (4.7 to 13.0)
8 21 3 15.9 (7.0 to 25.7)
0–8 2963 463 1.2 (1.0 to 1.4)
Women
1 16 6 0.3 (−0.4 to 0.8)
2 72 16 −0.1 (−0.6 to 0.3)
3 357 62 1.5 (1.1 to 1.9)
4 1065 144 2.4 (2.0 to 2.8)
5 803 92 3.1 (2.3 to 3.8)
6 997 78 8.0 (6.6 to 9.3)
7 536 30 6.8 (4.4 to 9.1)
8 164 15 12.4 (7.9 to 17.3)
9 32 0 16.8 (3.1 to 30.5)
1–9 4042 443 2.7 (2.4 to 3.0)
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multiple data sources, and adopting robust phenotypes for cap-
turing individuals, risk factors and end points. An example of
the value of CALIBER phenotypes comes from hypertension. As
shown, the proportion of individuals with baseline hypertension
rose signiﬁcantly when information from diagnosis codes was
supplemented with blood pressure measurements and prescrip-
tions data. It is however still possible that some individuals, risk
factors and end points may have been overlooked, but we con-
sider the number affected to be minimal, and less than previous
studies. While the lack of DOAC data may be considered a limi-
tation of the present analysis, it should be noted that warfarin
remains the most widely used oral anticoagulant. Therefore,
studies involving pre-DOAC era cohorts such as this are still
shown to be of contemporary relevance. Lastly, though we
included a large sample size of 70 000 individuals, we found
that only a quarter of the overall population had
CHA2DS2-VASc scores 0, 1 and 2. We therefore cannot rule out
the possibility that a positive NCB of warfarin may be observed
at CHA2DS2-VASc=1 given a larger study population.
CONCLUSION
CHA2DS2-VASc accurately stratiﬁes IS risk in individuals with
AF across both primary and secondary care. However IRs of IS
at CHA2DS2-VASc=1 are lower than previously reported, which
may change the decision to start anticoagulation with warfarin
in these individuals.
Key messages
What is already known on this subject?
It is unclear whether individuals with atrial ﬁbrillation (AF) and
CHA2DS2-VASc=1 beneﬁt from stroke prevention with warfarin.
Previous large-scale, population-based studies have reported
incidence of ischaemic stroke (IS) in individuals with
CHA2DS2-VASc=1; however have neglected the full patient
pathway by focusing on those with initial record of diagnosis in
secondary care.
What might this study add?
We conﬁrmed that CHA2DS2-VASc accurately stratiﬁes IS risk in
individuals with AF across both primary and secondary care,
however incidence rates (IRs) at CHA2DS2-VASc=1 are lower
than previously reported. We found a signiﬁcant positive net
clinical beneﬁt of warfarin from CHA2DS2-VASc≥2 in men and
from CHA2DS2-VASc≥3 in women, with 0.5 (0.1 to 0.9) and 1.5
(1.1 to 1.9) ISs avoided per 100 person-years of warfarin
treatment, respectively.
How might this impact on clinical practice?
IRs at CHA2DS2-VASc=1 are lower than previously reported,
which may change the decision to start anticoagulation with
warfarin in these individuals.
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